135 related articles for article (PubMed ID: 10749132)
1. Association of SRD5A2 genotype and pathological characteristics of prostate tumors.
Jaffe JM; Malkowicz SB; Walker AH; MacBride S; Peschel R; Tomaszewski J; Van Arsdalen K; Wein AJ; Rebbeck TR
Cancer Res; 2000 Mar; 60(6):1626-30. PubMed ID: 10749132
[TBL] [Abstract][Full Text] [Related]
2. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
Paz-y-Miño C; Witte T; Robles P; Llumipanta W; Díaz M; Arévalo M
Cancer Genet Cytogenet; 2009 Mar; 189(2):71-6. PubMed ID: 19215786
[TBL] [Abstract][Full Text] [Related]
3. [Association of polymorphisms in testosterone 5-alpha-reductase II genotype and prognosis factors of prostate cancer].
Tong M; Xu Z; Ai JK; Yuan YM; Yin Y; Wang JQ; Li HW; Liu JH; Xin DQ; Zhou LQ; Li M; Na YQ
Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(24):1493-6. PubMed ID: 15733480
[TBL] [Abstract][Full Text] [Related]
4. A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland.
Mononen N; Ikonen T; Syrjäkoski K; Matikainen M; Schleutker J; Tammela TL; Koivisto PA; Kallioniemi OP
Br J Cancer; 2001 May; 84(10):1344-7. PubMed ID: 11355945
[TBL] [Abstract][Full Text] [Related]
5. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
Giwercman YL; Abrahamsson PA; Giwercman A; Gadaleanu V; Ahlgren G
Eur Urol; 2005 Oct; 48(4):679-85. PubMed ID: 16039774
[TBL] [Abstract][Full Text] [Related]
6. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
[TBL] [Abstract][Full Text] [Related]
7. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
[TBL] [Abstract][Full Text] [Related]
8. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
Cussenot O; Azzouzi AR; Nicolaiew N; Mangin P; Cormier L; Fournier G; Valeri A; Cancel-Tassin G
Eur Urol; 2007 Oct; 52(4):1082-7. PubMed ID: 17448593
[TBL] [Abstract][Full Text] [Related]
9. [Association between A49T polymorphism of SRD5A2 gene and risk of prostate cancer].
Tong M; Ai JK; Yuan YM; Yin Y; Zhou LQ; Xin DQ; Li M; Na YQ
Zhonghua Yi Xue Za Zhi; 2005 May; 85(19):1319-21. PubMed ID: 16029630
[TBL] [Abstract][Full Text] [Related]
10. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.
Li Z; Habuchi T; Mitsumori K; Kamoto T; Kinoshitu H; Segawa T; Ogawa O; Kato T
J Urol; 2003 Jun; 169(6):2378-81. PubMed ID: 12771801
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis.
Shibata A; Garcia MI; Cheng I; Stamey TA; McNeal JE; Brooks JD; Henderson S; Yemoto CE; Peehl DM
Prostate; 2002 Sep; 52(4):269-78. PubMed ID: 12210487
[TBL] [Abstract][Full Text] [Related]
12. The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.
Scariano JK; Treat E; Alba F; Nelson H; Ness SA; Smith AY
Prostate; 2008 Dec; 68(16):1798-805. PubMed ID: 18780294
[TBL] [Abstract][Full Text] [Related]
13. The V89L polymorphism in the 5-alpha-reductase type 2 gene and risk of breast cancer.
van Gils CH; Onland-Moret NC; Roest M; van Noord PA; Peeters PH
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1194-9. PubMed ID: 14652280
[TBL] [Abstract][Full Text] [Related]
14. V89L polymorphism of the 5alpha-reductase Type II gene (SRD5A2), endogenous sex hormones, and prostate cancer risk.
Boger-Megiddo I; Weiss NS; Barnett MJ; Goodman GE; Chen C
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):286-91. PubMed ID: 18268111
[TBL] [Abstract][Full Text] [Related]
15. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
16. Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men.
Rajender S; Vijayalakshmi K; Pooja S; Madhavi S; Paul SF; Vettriselvi V; Shroff S; Singh L; Thangaraj K
J Androl; 2009; 30(6):703-10. PubMed ID: 19443907
[TBL] [Abstract][Full Text] [Related]
17. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.
Chang BL; Zheng SL; Isaacs SD; Turner AR; Bleecker ER; Walsh PC; Meyers DA; Isaacs WB; Xu J
Prostate; 2003 Jun; 56(1):37-44. PubMed ID: 12746845
[TBL] [Abstract][Full Text] [Related]
19. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
20. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
